JP2014512361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512361A5 JP2014512361A5 JP2014503699A JP2014503699A JP2014512361A5 JP 2014512361 A5 JP2014512361 A5 JP 2014512361A5 JP 2014503699 A JP2014503699 A JP 2014503699A JP 2014503699 A JP2014503699 A JP 2014503699A JP 2014512361 A5 JP2014512361 A5 JP 2014512361A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- mam
- polypeptide
- composition according
- pathogenic bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 244000052616 bacterial pathogen Species 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000002096 quantum dot Substances 0.000 claims description 3
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 2
- 241000312060 Escherichia coli HS Species 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 235000020247 cow milk Nutrition 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000007792 addition Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472440P | 2011-04-06 | 2011-04-06 | |
| US61/472,440 | 2011-04-06 | ||
| PCT/US2012/031552 WO2012138570A2 (en) | 2011-04-06 | 2012-03-30 | Modulating bacterial mam polypeptides in pathogenic disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512361A JP2014512361A (ja) | 2014-05-22 |
| JP2014512361A5 true JP2014512361A5 (enExample) | 2015-05-21 |
| JP6054371B2 JP6054371B2 (ja) | 2016-12-27 |
Family
ID=46969760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503699A Expired - Fee Related JP6054371B2 (ja) | 2011-04-06 | 2012-03-30 | 病原性疾患における細菌ｍａｍポリペプチドの調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9140698B2 (enExample) |
| EP (1) | EP2693887B1 (enExample) |
| JP (1) | JP6054371B2 (enExample) |
| AU (1) | AU2012240395B2 (enExample) |
| CA (1) | CA2832443C (enExample) |
| WO (1) | WO2012138570A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
| US10416167B2 (en) | 2012-02-17 | 2019-09-17 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
| EP2833911A4 (en) | 2012-04-06 | 2016-07-13 | Univ Cornell | SUB-VACCINE VACCINATING PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES |
| US9815871B2 (en) | 2013-04-23 | 2017-11-14 | President And Fellows Of Harvard College | Genetic reprogramming of bacterial biofilms |
| EP3039733B1 (en) * | 2013-08-29 | 2018-11-21 | Northeastern University | Matrix-enhanced electrochemical detector for pathogenic bacteria |
| US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
| JP6916524B2 (ja) | 2015-04-06 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 機能的タンパク質配列をディスプレイする生合成アミロイドに基づく材料 |
| US11098133B2 (en) | 2016-05-19 | 2021-08-24 | President And Fellows Of Harvard College | Methods of making gels and films using curli nanofibers |
| CA3214423A1 (en) * | 2017-02-17 | 2018-08-23 | The University Of British Columbia | Probiotic compositions and uses thereof |
| EP3720458A4 (en) | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| GB202003062D0 (en) | 2020-03-03 | 2020-04-15 | Univ Sheffield | Antimicrobial target |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| CN111848734B (zh) * | 2020-06-17 | 2022-04-05 | 自然资源部第三海洋研究所 | 一种具有荧光特性的铁载体pvd、制备方法及其用途 |
| CN112007143B (zh) * | 2020-08-19 | 2023-09-22 | 中山大学 | 重组副溶血弧菌鞭毛蛋白在提高鱼类免疫力中的应用 |
| WO2024059139A2 (en) * | 2022-09-13 | 2024-03-21 | University Of Cincinnati | Engineered probiotics expressing anti-inflammatory molecules |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE69126607T2 (de) | 1990-01-23 | 1998-01-15 | Tanox Biosystems, Inc., Houston, Tex. | Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| AU1570292A (en) | 1991-02-07 | 1992-09-07 | Board Of Trustees Of The University Of Illinois, The | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
| US5929237A (en) | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6444444B1 (en) * | 1996-07-10 | 2002-09-03 | Aventis Pasteur Limited | Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof |
| US6284255B1 (en) | 1996-08-29 | 2001-09-04 | Genesis Research & Development Corporation Limited | Compounds and methods for treatment and diagnosis of mycobacterial infections |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7223558B2 (en) * | 2001-07-11 | 2007-05-29 | Bristol-Myers Squibb Company | Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof |
| US20030138490A1 (en) | 2001-09-08 | 2003-07-24 | Zhibing Hu | Synthesis and uses of polymer gel nanoparticle networks |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| WO2004089421A2 (en) | 2003-03-31 | 2004-10-21 | Xencor, Inc | Methods for rational pegylation of proteins |
| JP2007530034A (ja) * | 2004-03-23 | 2007-11-01 | エヌ．ブイ．・ヌートリシア | 新規のマンノース特異的アドヘシンとその使用 |
| GB0423126D0 (en) * | 2004-10-18 | 2004-11-17 | Ares Trading Sa | Protein |
| US20090048160A1 (en) * | 2007-08-17 | 2009-02-19 | Bannerman Douglas D | Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates |
| US8110656B2 (en) * | 2008-07-22 | 2012-02-07 | Board Of Trustees Of Michigan State University | Compositions and methods of a phosphatidic acid binding protein |
-
2012
- 2012-03-30 US US14/009,724 patent/US9140698B2/en not_active Expired - Fee Related
- 2012-03-30 AU AU2012240395A patent/AU2012240395B2/en not_active Ceased
- 2012-03-30 EP EP12767481.0A patent/EP2693887B1/en not_active Not-in-force
- 2012-03-30 JP JP2014503699A patent/JP6054371B2/ja not_active Expired - Fee Related
- 2012-03-30 WO PCT/US2012/031552 patent/WO2012138570A2/en not_active Ceased
- 2012-03-30 CA CA2832443A patent/CA2832443C/en not_active Expired - Fee Related
-
2015
- 2015-09-22 US US14/861,709 patent/US9529005B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512361A5 (enExample) | ||
| Wang et al. | Enhanced viability of layer-by-layer encapsulated Lactobacillus pentosus using chitosan and sodium phytate | |
| Manzoni et al. | Prevention of nosocomial infections in neonatal intensive care units | |
| Yeung et al. | Microencapsulation in alginate and chitosan microgels to enhance viability of Bifidobacterium longum for oral delivery | |
| Priya et al. | Enhanced survival of probiotic Lactobacillus acidophilus by encapsulation with nanostructured polyelectrolyte layers through layer-by-layer approach | |
| CA2825473C (en) | Protection of microbial cells from acidic degradation | |
| AU2018201590A1 (en) | Compositions for the restoration of a fecal microbiota and methods for making and using them | |
| CN106511380A (zh) | 一种粪菌组合物及其制备方法和用途 | |
| Reddy et al. | Applications, challenges, and strategies in the use of nanoparticles as feed additives in equine nutrition | |
| AU2012210575A1 (en) | Protection of microbial cells from acidic degradation | |
| CN101912046B (zh) | 猪源植物乳杆菌微胶囊及其应用 | |
| Naklong et al. | Microencapsulation of Bifidobacterium breve to enhance microbial cell viability in green soybean yogurt | |
| Rodríguez et al. | Infectious mastitis during lactation: a mammary dysbiosis model | |
| WO2020028871A1 (en) | Prenatal probiotic formulations | |
| AL-Fawares et al. | Development of Chitosan-Polyacrylic acid complex systems for enhanced oral delivery of Lactobacillus Gasseri and Bifidobacterium Bifidum probiotics | |
| Shi et al. | Milk-alginate microspheres: Protection and delivery of Enterococcus faecalis HZNU P2 | |
| Zheng et al. | Functional modification of gut bacteria for disease diagnosis and treatment | |
| Wang et al. | Effect of Microencapsulation Techniques on the Stress Resistance and Biological Activity of Bovine Lactoferricin-Lactoferrampin-Encoding Lactobacillus reuteri | |
| Pandey et al. | The potential of nanoencapsulated probiotics in the modulation of the gut microbiome | |
| US10111905B2 (en) | Antibacterial pharmaceutical preparation | |
| TWI384990B (zh) | 用於治療胃潰瘍之乳酸菌菌株之食品組成物以及醫藥組成物 | |
| CN102835666B (zh) | 用于治疗胃溃疡的乳酸菌菌株的食品组合物以及医药组合物 | |
| Collado et al. | Baby’s first microbes: The microbiome of human milk | |
| Baheti et al. | Different formulation approaches to improve the survivability of probiotics in the digestive tract | |
| Alli | Preparation and characterization of a coacervate extended-release microparticulate delivery system for Lactobacillus rhamnosus |